LXR agonism and Sorafenib treatment as novel combination therapy for hepatocellular carcinoma

Subjects

Subjects :

Combination therapy
business.industry
Sorafenib treatment
medicine.disease
Biochemistry
Hepatocellular carcinoma
Genetics
medicine
Cancer research
Agonism
business
Liver X receptor
Molecular Biology
Biotechnology

Details

ISSN :

15306860 and 08926638

Volume :

33

Database :

OpenAIRE

Journal :

The FASEB Journal

Accession number :

edsair.doi...........278bb8a47ee529ed2f5bf5b9df005788

Full Text :

https://doi.org/10.1096/fasebj.2019.33.1_supplement.126.9